http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017109488-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09b9da38b5c12ebd0c65d66149fc99bf
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
filingDate 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14da0c842cba98e56c09238aa54fd735
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a784c2089b40a6bbcc8dd5444c5621
publicationDate 2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2017109488-A8
titleOfInvention Cyanopyrrolidine derivatives as inhibitors for dubs
abstract The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Compounds of the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R 1a , R 1b , R 1c , R 1d , R 1e , R 1f and A are as defined herein.
priorityDate 2015-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100756
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415751341
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID304579
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID733894
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID84749
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID31519
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73737
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID559099

Total number of triples: 35.